Discover
IVA
Inventiva S.A.
3.69
1 x 3.40
1 x 3.78
bid
ask
-
0.09
2.38%
1 @ 04:00 PM
3.72 +0.03 (0.81%)
| Ytd | -20.65% | |
| 1y | 23.83% |
3.53
day range
3.79
2.85
52 week range
7.98
| Open | 3.75 | Prev Close | 3.78 | Low | 3.53 | High | 3.79 | Mkt Cap | 871.65M |
| Vol | 1.71M | Avg Vol | 668.04K | EPS | -2.16 | P/E | N/A | Forward P/E | -5.23 |
| Beta | 0.88 | Short Ratio | 2.14 | Inst. Own | 27.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-30 | 50-d Avg | 4.61 | 200-d Avg | 5.19 | 1yr Est | 15.13 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-03-30 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-03-26 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-03-27 | 2023-12 | 0 | N/A | N/A | N/A |
| 2023-09-28 | 2023-06 | 0 | N/A | N/A | N/A |
| 2023-03-29 | 2022-12 | 0 | N/A | N/A | N/A |
| 2022-08-01 | 2022-03 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-03-19 | Truist Securities | Upgrade | Buy | |
| 2026-01-28 | Barclays | Upgrade | Overweight | |
| 2026-01-12 | Leerink Partners | Upgrade | Outperform | |
| 2025-11-18 | Guggenheim | Upgrade | Buy | Buy |
| 2025-11-06 | Wolfe Research | Upgrade | Outperform | |
| 2025-10-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Samsara BioCapital, LLC | 5.19M | 24.78M | 2.49% |
| 2026-03-30 | Caligan Partners, LP | 4.97M | 23.73M | 2.38% |
| 2026-03-30 | Paradigm Biocapital Advisors LP | 4.00M | 19.08M | 1.91% |
| 2026-03-30 | Millennium Management Llc | 2.99M | 14.25M | 1.43% |
| 2026-03-30 | Trails Edge Capital Partners, LP | 2.66M | 12.68M | 1.27% |
| 2026-03-30 | Franklin Resources, Inc. | 2.46M | 11.74M | 1.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-01-30 | Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | 908.00K | 4.33M | 0.43% |
| 2026-03-30 | Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 227.92K | 1.09M | 0.11% |
| 2026-01-30 | RUSSELL INVESTMENT CO-U.S. Small Cap Equity Fund | 35.42K | 168.97K | 0.02% |
| 2026-03-30 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 31.48K | 150.17K | 0.02% |
| 2026-03-30 | RUSSELL INVESTMENT FUNDS-U.S. Small Cap Equity Fund | 9.22K | 43.98K | 0.00% |
| 2026-04-29 | iShares Trust-iShares International Small-Cap Equity Factor ETF | 8.58K | 40.93K | 0.00% |